Ion channel gene expression predicts survival in glioma patients

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Rong ^a   Gurguis, Christopher I ^b   Gu, Wanjun ^c   Ko, Eun A ^d   Lim, Inja ^e   Bang, Hyoweon ^e   Zhou, Tong ^b   Ko, Jae Hong ^e  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c SOUTHEAST UNIVERSITY   (China)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^e Chung Ang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; TUMOR MARKER;

CANCER GRADING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

BIOMARKERS, TUMOR; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; ION CHANNELS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84938517742     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11593     Document Type: Article

References (60)

1. Camerino, D. C., Tricarico, D., Desaphy, J. F. Ion channel pharmacology. Neurotherapeutics 4, 184-198 (2007).
2. Hubner, C. A., Jentsch, T. J. Ion channel diseases. Hum. Mol. Genet. 11, 2435-2445 (2002).
3. Yang, N. et al. Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc. Natl. Acad. Sci. USA 91, 12785-12789 (1994).
4. Zerr, P., Adelman, J. P., Maylie, J. Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency. J. Neurosci. 18, 2842-2848 (1998).
5. Carrera, P., Stenirri, S., Ferrari, M., Battistini, S. Familial hemiplegic migraine: a ion channel disorder. Brain Res. Bull. 56, 239-241 (2001).
6. Welsh, M. J. Abnormal regulation of ion channels in cystic fibrosis epithelia. FASEB J. 4, 2718-2725 (1990).
7. Lastraioli, E., Iorio, J., Arcangeli, A. Ion channel expression as promising cancer biomarker. Biochim. Biophys. Acta. doi:10.1016/j. bbamem.2014.12.016 (2014).
8. Palmieri, C. et al. Methylation of the calcium channel regulatory subunit alpha2delta-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br. J. Cancer 107, 375-381 (2012).
9. Lastraioli, E. et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64, 606-611 (2004).
10. Ma, X. et al. alpha5 Nicotinic acetylcholine receptor mediates nicotine-induced HIF-1alpha and VEGF expression in non-small cell lung cancer. Toxicol. Appl. Pharmacol. 278, 172-179 (2014).
11. Ko, J. H. et al. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol. Cancer 12, 106 (2013).
12. Ko, J. H. et al. Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. PLoS One 9, e86569 (2014).
13. Ko, J. H., Gu, W., Lim, I., Zhou, T., Bang, H. Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomas. PLoS One 9, e110094 (2014).
14. Furnari, F. B. et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007).
15. Stupp, R., Tonn, J. C., Brada, M., Pentheroudakis, G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl 5), , v190-193 (2010).
16. Verkhratsky, A., Steinhauser, C. Ion channels in glial cells. Brain Res. Brain Res. Rev. 32, 380-412 (2000).
17. Molenaar, R. J. Ion channels in glioblastoma. ISRN Neurol. 2011, 590249 (2011).
18. McFerrin, M. B., Sontheimer, H. A role for ion channels in glioma cell invasion. Neuron Glia Biol. 2, 39-49 (2006).
19. Sontheimer, H. An unexpected role for ion channels in brain tumor metastasis. Exp. Biol. Med. (Maywood) 233, 779-791 (2008).
20. Weaver, A. K., Liu, X., Sontheimer, H. Role for calcium-activated potassium channels (BK) in growth control of human malignant glioma cells. J. Neurosci. Res. 78, 224-234 (2004).
21. Chin, L. S. et al. 4-Aminopyridine causes apoptosis and blocks an outward rectifier K+ channel in malignant astrocytoma cell lines. J. Neurosci. Res. 48, 122-127 (1997).
22. Krex, D. et al. Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606 (2007).
23. Henriksen, M., Johnsen, K. B., Andersen, H. H., Pilgaard, L., Duroux, M. MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme-a systematic overview. Mol. Neurobiol. 50, 896-913 (2014).
24. Henriksen, M., Johnsen, K. B., Olesen, P., Pilgaard, L., Duroux, M. MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme. Neuromolecular Med. 16, 565-577 (2014).
25. Meng, J., Li, P., Zhang, Q., Yang, Z., Fu, S. A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway. Oncotarget 5, 4683-4693 (2014).
26. Patel, V. N. et al. Network signatures of survival in glioblastoma multiforme. PLoS Comput. Biol. 9, e1003237 (2013).
27. Vital, A. L. et al. Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro. Oncol. 12, 991-1003 (2010).
28. Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., Wrensch, M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2, 494-503 (2006).
29. Sun, L. et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9, 287-300 (2006).
30. Erdem-Eraslan, L. et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J. Clin. Oncol. 31, 328-336 (2013).
31. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 (2006).
32. Nutt, C. L. et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602-1607 (2003).
33. Venet, D., Dumont, J. E., Detours, V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 7, e1002240 (2011).
34. van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344-350 (2013).
35. Yang, S., Zhang, J. J., Huang, X. Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 15, 124-134 (2009).
36. Jang, S. H., Choi, S. Y., Ryu, P. D., Lee, S. Y. Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma in vitro and in vivo. Eur. J. Pharmacol. 651, 26-32 (2011).
37. House, C. D. et al. Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res. 70, 6957-6967 (2010).
38. Bode, A. M. et al. Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res. 69, 905-913 (2009).
39. Fusi, C. et al. Transient receptor potential vanilloid 4 (TRPV4) is downregulated in keratinocytes in human non-melanoma skin cancer. J. Invest. Dermatol. 134, 2408-2417 (2014).
40. Chen, R. et al. Cav1.3 channel alpha1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol. Oncol. 32, 524-536 (2014).
41. Suh, K. S., Yuspa, S. H. Intracellular chloride channels: critical mediators of cell viability and potential targets for cancer therapy. Curr. Pharm. Des. 11, 2753-2764 (2005).
42. Leja, J. et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod. Pathol. 22, 261-272 (2009).
43. Felipe, A. et al. Potassium channels: new targets in cancer therapy. Cancer Detect. Prev. 30, 375-385 (2006).
44. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
45. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
46. Eichelbaum, M., Ingelman-Sundberg, M., Evans, W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
47. Shoshan-Barmatz, V., Mizrachi, D. VDAC1: from structure to cancer therapy. Front. Oncol. 2, 164 (2012).
48. Schrey, M. et al. Molecular characterization of voltage-gated sodium channels in human gliomas. Neuroreport 13, 2493-2498 (2002).
49. Preussat, K. et al. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas. Neurosci. Lett. 346, 33-36 (2003).
50. Lee, U. S., Cui, J. BK channel activation: structural and functional insights. Trends Neurosci. 33, 415-423 (2010).
51. Ransom, C. B., Liu, X., Sontheimer, H. BK channels in human glioma cells have enhanced calcium sensitivity. Glia 38, 281-291 (2002).
52. Liu, X., Chang, Y., Reinhart, P. H., Sontheimer, H. Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J. Neurosci. 22, 1840-1849 (2002).
53. Ransom, C. B., Sontheimer, H. BK channels in human glioma cells. J. Neurophysiol. 85, 790-803 (2001).
54. Plomin, R., Haworth, C. M., Davis, O. S. Common disorders are quantitative traits. Nat. Rev. Genet. 10, 872-878 (2009).
55. Sonnenschein, C., Soto, A. M., Rangarajan, A., Kulkarni, P. Competing views on cancer. J. Biosci. 39, 281-302 (2014).
56. Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
57. Liu, W. M. et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 18, 1593-1599 (2002).
58. Pitroda, S. P. et al. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One 7, e46104 (2012).
59. Zhou, T., Wang, T., Garcia, J. G. Genes influenced by the non-muscle isoform of Myosin light chain kinase impact human cancer prognosis. PLoS One 9, e94325 (2014).
60. Zhou, T., Wang, T., Garcia, J. G. Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrencefree survival in lung and breast cancers. Sci. Rep. 4, 6107 (2014).